A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.

CompletadoFase 2ClinicalTrials.gov

ID: NCT00808288Tipo: INTERVENTIONALInicio: 1 de mar de 2010Fin estimado: 1 de dic de 2010

Neumología

Traducción no disponible, mostrando original

Resumen

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Elegibilidad

Edad mínima: 40 YearsEdad máxima: 80 YearsSexo: ALL

Criterios de inclusión

Post-bronchodilator FEV1/FVC ratio \<0.7 and a post-bronchodilator FEV1 of 50-80%.
Diagnosis of moderate COPD for a minimum of 6 months.
Stable disease for at least 1 month prior to screening

Criterios de exclusión

More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.

Intervenciones

drug

PF-00610355

oral, inhaled, dry powder, 600ug, OD

drug

PF - 00610355

oral, inhaled, dry powder, 300ug, OD

drug

PF- 00610355

oral, inhaled, dry powder, 100ug, OD

drug

Placebo

oral, inhaled, dry powder, placebo, OD

drug

Salmeterol

salmeterol, 50ug, BID

Ubicaciones

Pfizer Investigational Site

Rosario, Santa Fe Province, Argentina

Pfizer Investigational Site

Buenos Aires, Argentina

Pfizer Investigational Site

Buenos Aires, Argentina

Patrocinadores

PrincipalPfizer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 2b, Parallel Group, Placebo And Active Comparator... | EligiMed